| Symbol | GLUE |
|---|---|
| Name | MONTE ROSA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 645 SUMMER STREET,SUITE 102, BOSTON, Massachusetts, 02210, United States |
| Telephone | +1 617 949-2643 |
| Fax | — |
| — | |
| Website | https://www.monterosatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001826457 |
| Description | Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the bodys natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Additional info from NASDAQ: |
Warmuth Markus 🔴 sold 9.5K shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.18 Transaction Date: Jul 16, 2026 | Filing ID: 307791
Read moreChampoux Jennifer 🟡 adjusted position in 4.4K shares (1 derivative) of Monte Rosa Therapeutics, Inc. (GLUE) at $23.38 Transaction Date: Jul 15, 2026 | Filing ID: 306110
Read more📋 MARKUS WARMUTH (Officer) plans to sell 10K shares of MONTE ROSA THERAPEUTICS, INC. (at $23.18 each, total $220K) Filed: Jul 16, 2026 | ID: 007144
Read more📋 Champoux Jennifer (Officer) plans to sell 4K shares of Monte Rosa Therapeutics, Inc. (at $23.38 each, total $102K) Filed: Jul 15, 2026 | ID: 000786
Read moreTownson Sharon 🟡 adjusted position in 6.0K shares (1 derivative) of Monte Rosa Therapeutics, Inc. (GLUE) at $24.13 Transaction Date: Jul 06, 2026 | Filing ID: 297558
Read moreBehbahani Ali 🟡 adjusted position in 1.0M shares of Monte Rosa Therapeutics, Inc. (GLUE) Transaction Date: Jul 01, 2026 | Filing ID: 296490
Read moreNew Form SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001072613-26-000558 <b>Size:</b> 88 KB
Read moreMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more📋 FILIP JANKU (Officer) plans to sell 6K shares of MONTE ROSA THERAPEUTICS INC (at $22.29 each, total $134K) Filed: Jun 29, 2026 | ID: 006612
Read more📋 ANTHONY M MANNING (Director) plans to sell 10K shares of MONTE ROSA THERAPEUTICS, INC. (at $23.11 each, total $231K) Filed: Jun 29, 2026 | ID: 006574
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer | Phase2 | Castration-Resistant Prostate Cancer (CRPC) | Recruiting | 2026-08-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT07119125 | A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Particip… | Phase1 | Healthy Volunteers | Active_Not_Recruiting | 2025-06-27 | 2026-07-01 | ClinicalTrials.gov |
| NCT06597799 | First-in-human Study of MRT-6160 in Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2024-08-07 | 2025-04-10 | ClinicalTrials.gov |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | Phase1 | NSCLC | Active_Not_Recruiting | 2022-10-12 | 2027-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Apalutamide | Other | Phase PHASE2 | Castration-Resistant Prostate Cancer (CRPC) | RECRUITING | NCT07745361 |
| Oral MRT-2359 | Other | Phase PHASE2 | Castration-Resistant Prostate Cancer (CRPC) | RECRUITING | NCT07745361 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07119125 |
| MRT-8102 | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07119125 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06597799 |
| MRT-6160 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06597799 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| MRT-8102 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| Oral MRT-2359 | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05546268 |
| MRT-8102 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| MRT-6160 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06597799 |
| Oral MRT-2359 | DRUG | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05546268 |